As part of its latest reprimand of Pfizer Inc for illegal marketing activities, the government has decided that the drugmaker’s general counsel should no longer oversee the company’s compliance program.
The size of the U.S. Department of Justice’s settlement with Pfizer, announced September 2, was what drew the most attention. The company agreed to pay $2.3 billion to resolve allegations that its executives and sales staff illegally marketed the painkiller Bextra and several other drugs. But the government also insisted that Pfizer’s chief compliance officer must now report to the company’s CEO instead of its GC. The settlement is the fourth that Pfizer has reached with Justice over illegal marketing since 2002, and the largest such deal in the department’s history.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
